Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Jessica Rimsans"'
Publikováno v:
Thrombosis Update, Vol 5, Iss , Pp 100076- (2021)
Background: Both andexanet alfa and 4F-PCC reversal strategies have been associated with thrombotic events. It remains unclear whether the risk is associated with the reversal agent or the lack of re-initiation of anticoagulation. Objective: The aim
Externí odkaz:
https://doaj.org/article/32e0f2c793b840a1bdd6396d649c7638
Autor:
Jessica Rimsans, Karen Berger, Sarah Culbreth, Christopher Hood, Katleen Chester, Jean M. Connors, Laurel Omert
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 5, Iss 8, Pp n/a-n/a (2021)
Abstract Background Four‐factor prothrombin complex concentrate (4F‐PCC) dosing is based on INR and actual body weight (ABW), with maximum doses not to exceed the dose used in patients weighing >100 kg (Kcentra PI). There are limited data compari
Externí odkaz:
https://doaj.org/article/a61a94d5c802477ba92b9e602ad64ac3
Autor:
Julie Kelly, Katelyn W. Sylvester, Jessica Rimsans, Thomas D. Bernier, Clara Ting, Jean M. Connors
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 5, Iss 5, Pp n/a-n/a (2021)
Abstract Background Diagnosing heparin‐induced thrombocytopenia (HIT) in patients with end‐stage renal disease (ESRD) can be difficult, as they are frequently exposed to heparin and have multiple etiologies for thrombocytopenia. Objective To corr
Externí odkaz:
https://doaj.org/article/f8f5e42ce2c1431db56e29c5e96cd0b8
Autor:
Kevin McLaughlin PharmD, BCPS, Jessica Rimsans PharmD, BCPS, Katelyn W. Sylvester PharmD, BCPS, CACP, John Fanikos Rph, MBA, David M. Dorfman MD, PhD, Patricia Senna MT, ASCP, Jean M. Connors MD, Samuel Z. Goldhaber MD
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 25 (2019)
Clinical uncertainty exists regarding which assay should be designated as the standard monitoring coagulation test for intravenous unfractionated heparin (UFH). Several studies have compared the use of activated partial thromboplastin time (aPTT) and
Externí odkaz:
https://doaj.org/article/2148780617d4410ba974e4acd62cb95c
Autor:
Amy A. Levesque PharmD, Andrea R. Lewin PharmD, Jessica Rimsans PharmD, Katelyn W. Sylvester PharmD, Lara Coakley NP, Frank Melanson RN, Hari Mallidi MD, Mandeep Mehra MD, Michael M. Givertz MD, Jean M. Connors MD
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 25 (2019)
Patients receiving durable mechanical circulatory support (MCS) require life-long anticoagulation with a vitamin K antagonist (VKA). Due to alternations in hemostasis, concomitant therapy with antiplatelet agents and critical illness, they are at inc
Externí odkaz:
https://doaj.org/article/237456225c7a46768f1e46f885c6fb94
Publikováno v:
Transplantation. 106:2143-2154
Direct-acting oral anticoagulant (DOAC) use has increased dramatically since their introduction because of the growing evidence of proven efficacy and enhanced safety compared with warfarin and the low-molecular-weight heparins in the general populat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8fe6140042a67687f3771bbfdd74a0b
https://doi.org/10.1097/tp.0000000000004195
https://doi.org/10.1097/tp.0000000000004195
Publikováno v:
Current Pharmacology Reports. 6:241-259
The introduction of newer anticoagulants requires clinicians to fully appreciate, interpret, and correctly apply the use of coagulation assays, such as the prothrombin time (PT), activated partial thromboplastin time (APTT), and anti-factor Xa assays
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aa7b916f6406804903d1ac400be002ca
https://doi.org/10.1007/s40495-020-00232-7
https://doi.org/10.1007/s40495-020-00232-7
Publikováno v:
ASAIO Journal. 66:482-488
Durable left ventricular assist device (LVAD) recipients require long-term anticoagulation to prevent thromboembolic complications. Their management is complicated by the risk of bleeding, which may require rapid anticoagulation reversal. We conducte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e460b522fd51adcf7d139e4e1410d091
https://doi.org/10.1097/mat.0000000000001021
https://doi.org/10.1097/mat.0000000000001021
Publikováno v:
Thrombosis Update, Vol 5, Iss, Pp 100076-(2021)
Background Both andexanet alfa and 4F-PCC reversal strategies have been associated with thrombotic events. It remains unclear whether the risk is associated with the reversal agent or the lack of re-initiation of anticoagulation. Objective The aim of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70301677843b46121381a64e8bc7a0de
http://www.sciencedirect.com/science/article/pii/S2666572721000456
http://www.sciencedirect.com/science/article/pii/S2666572721000456
Autor:
Katleen Chester, Jean M. Connors, Laurel Omert, Christopher Hood, Jessica Rimsans, Sarah E Culbreth, Karen Berger
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 5, Iss 8, Pp n/a-n/a (2021)
Research and Practice in Thrombosis and Haemostasis
Research and Practice in Thrombosis and Haemostasis
Background Four‐factor prothrombin complex concentrate (4F‐PCC) dosing is based on INR and actual body weight (ABW), with maximum doses not to exceed the dose used in patients weighing >100 kg (Kcentra PI). There are limited data comparing the ef
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a77d8d1010a4df66f174951d58c6ce9
https://doaj.org/article/a61a94d5c802477ba92b9e602ad64ac3
https://doaj.org/article/a61a94d5c802477ba92b9e602ad64ac3